Hepatology, Journal Year: 2024, Volume and Issue: 81(1), P. 7 - 8
Published: Dec. 16, 2024
Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA Abbreviations: aHR, adjusted hazard ratio; MASLD, metabolic dysfunction–associated steatotic liver disease; MetALD, dysfunction- and alcohol-associated NHANES III, Third National Health Nutrition Examination Survey. Correspondence Hendrien Kuipers, MN, 55905 USA. Email: [email protected]
Language: Английский
The Lancet, Journal Year: 2024, Volume and Issue: 404(10464), P. 1761 - 1778
Published: Nov. 1, 2024
Language: Английский
Citations
30
Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: July 1, 2024
Language: Английский
Citations
4
Hepatology International, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 16, 2024
Abstract Background The international consensus to revise non-alcoholic fatty liver disease metabolic (dysfunction)-associated (MAFLD) in 2020 attracted significant attention. impact of the MAFLD definition on research community has not been objectively assessed. We conducted an analysis systematically collected literature understand its impact. Methods From PubMed, Web Science, and Scopus, adopting MAFLD, written English, published from 10 October 2023 was collected. publication metrics, including counts, publishing journals, author countries, keywords, citation information, were analyzed evaluate key topics MAFLD. Results 1469 MAFLD-related papers 434 journals with a steady increase number. intense citations activity indicates large redefinition. Topic assessment keyword revealed transition proposal discussion redefinition clinical characterization focus dysfunction. Moreover, diagnostic criteria for showed better performance predicting hepatic extrahepatic outcomes compared NAFLD. publications 99 countries evidence strong regional global collaboration. Multiple societies stakeholders have endorsed utility practice, improving patient management promoting multidisciplinary care, while alleviating stigma. Conclusion This survey provides quantitative measure considerable contributions towards as part spectrum cardiometabolic disorders.
Language: Английский
Citations
4
Journal of Global Health, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 16, 2025
Prehypertension and hypertension often coexist with non-alcoholic fatty liver disease (NAFLD) during the progression of cardiovascular (CVD). International academic societies have recently reached a consensus to replace NAFLD new term 'steatotic disease' (SLD). In this study, we aimed evaluate impact different SLD subtypes on all-cause CVD mortality in individuals prehypertension or hypertension. We included 6074 adults from National Health Nutrition Examination Survey (2003-18). The US index was used as diagnostic criterion for SLD, participants were classified into no metabolic dysfunction-associated steatotic (MASLD), alcohol-related (MetALD), (ALD). For cases MASLD, MetALD, ALD, further assessed advanced fibrosis using fibrosis-4 (FIB-4) index. Additionally, calculated hazard ratios (HRs) 95% confidence intervals (CIs) Cox proportional hazards regression models assess associations mortality. There 3505 (57.7%) 1284 (21.1%) 777 (12.8%) 508 (8.4%) ALD. During median follow-up period 8.2 years, risk progressively increased MASLD (HR = 1.28; CI 1.01-1.63 HR 1.55; 1.04-2.33, respectively), MetALD 1.41; 1.05-1.88 1.78; 1.10-2.87, ALD 1.83; 1.32-2.53 1.80; 1.01-3.19, respectively). Among also associated an Individuals had higher than those without SLD. Therefore, early intervention strategies targeting prevention management may help improve their long-term health.
Language: Английский
Citations
0
Annals of Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 101907 - 101907
Published: March 1, 2025
Language: Английский
Citations
0
The American Journal of Medicine, Journal Year: 2024, Volume and Issue: 137(11), P. 1072 - 1081.e32
Published: July 22, 2024
Language: Английский
Citations
3
Nutrients, Journal Year: 2025, Volume and Issue: 17(2), P. 244 - 244
Published: Jan. 10, 2025
Metabolic dysfunction associated steatotic liver disease (MASLD) has been with increased risks of all-cause and cardiovascular (CVD) mortality. Identification modifiable risk factors that may contribute to higher mortality could facilitate targeted intensive intervention strategies in this population. This study aims examine whether the magnesium depletion score (MDS) is CVD among individuals MASLD or metabolic alcohol (MetALD). A total 3802 participants MetALD were followed up over a median 26 years National Health Nutrition Examination Survey (NHANES) III cohort. The MDS was calculated by aggregating four influencing reabsorption capability kidneys. associations between all-cause, CVD, cancer quantified using Cox proportional hazard regression models. In combined + cohort, (>2) (HR, 2.52; 95%CI, 1.77-3.61; p-trend < 0.0001) 3.01; 1.87-4.86; compared = 0; association became stronger who did not meet estimated average requirement level Mg intake (2.72; 1.69-4.37; 0.0014) those Fibrosis-4 index (FIB-4) 1.3 (2.95; 1.69-5.15; 0.0006). MetALD, MDS, indicative worse global status, an Correcting deficiency high-risk MASLD/MetALD patients have long-term health benefits.
Language: Английский
Citations
0
BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)
Published: Feb. 11, 2025
Steatotic liver disease (SLD) was a newly proposed category derived from metabolic dysfunction-associated fatty (MAFLD). MAFLD and sarcopenia were independent risk factors for mortality. We aimed to evaluate the impacts of SLD subtypes, MAFLD, on A total 6543 subjects identified National Health Nutrition Examination Survey 1999–2006 with latest Linked Mortality file. Hepatic steatosis, advanced fibrosis, determined by laboratory- anthropometry- based index fibrosis-4 index, dual-energy X-ray absorptiometry-based appendicular skeletal muscle mass respectively. Associations mortality estimated using weighted Cox proportional hazards model. During mean follow-up time 15.7 years, 1567 (16.7%) deaths occurred including 494 (4.9%) cardiovascular diseases 372 (4.1%) cancer. The all-cause rates steatotic (MASLD), dysfunction alcohol-associated (MetALD), other aetiology SLD, MASLD without sarcopenia, 21.0%, 19.8%, 30.2%, 30.9%, 19.2%, 75.5%, increased (hazard ratio [HR] 1.26, 95% confidence interval [CI] 1.00-1.59). predicted (HR 1.17, CI 1.03–1.33) but this prediction became insignificant after adjustment risks. In contrast, MetALD significantly associated 1.83, 1.21–2.76; HR 2.50, 1.82–3.44, respectively), predominantly cancer-specific 2.42, 1.23–4.74; 2.49, 1.05–5.90, respectively). almost twice 2.19, 1.37–3.49) further coexisting fibrosis additively 3.41, 1.92–6.05). definition more homogeneous group metabolically hepatic steatosis at higher risks or MASLD-related
Language: Английский
Citations
0
Atherosclerosis, Journal Year: 2025, Volume and Issue: 403, P. 119161 - 119161
Published: March 7, 2025
Language: Английский
Citations
0
Liver International, Journal Year: 2025, Volume and Issue: 45(5)
Published: April 3, 2025
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.
Language: Английский
Citations
0